Share-based Payment Arrangement, Expense of Cardiff Oncology, Inc. from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cardiff Oncology, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
  • Cardiff Oncology, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,384,000, a 10% increase year-over-year.
  • Cardiff Oncology, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,636,000, a 26% increase year-over-year.
  • Cardiff Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,760,000, a 5.6% increase from 2023.
  • Cardiff Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4,509,000, a 5.9% increase from 2022.
  • Cardiff Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4,256,000, a 32% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cardiff Oncology, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,636,000 $1,384,000 +$131,000 +10% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $5,505,000 $1,683,000 +$504,000 +43% 01 Apr 2025 30 Jun 2025 10-Q 29 Jul 2025 2025 Q2
Q1 2025 $5,001,000 $1,365,000 +$241,000 +21% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $4,760,000 $1,204,000 +$295,000 +32% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $4,465,000 $1,253,000 +$298,000 +31% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $4,167,000 $1,179,000 -$402,000 -25% 01 Apr 2024 30 Jun 2024 10-Q 29 Jul 2025 2025 Q2
Q1 2024 $4,569,000 $1,124,000 +$60,000 +5.6% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $4,509,000 $909,000 -$103,000 -10% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $4,612,000 $955,000 -$82,000 -7.9% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $4,694,000 $1,581,000 +$526,000 +50% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $4,168,000 $1,064,000 -$88,000 -7.6% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $4,256,000 $1,012,000 +$22,000 +2.2% 01 Oct 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $4,234,000 $1,037,000 +$97,000 +10% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $4,137,000 $1,055,000 +$19,000 +1.8% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $4,118,000 $1,152,000 +$884,000 +330% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $3,234,000 $990,000 +$46,000 +4.9% 01 Oct 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 $3,188,000 $940,000 +$578,000 +160% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $2,610,000 $1,036,000 +$754,000 +267% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $1,856,000 $268,000 +$91,000 +51% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $1,765,000 $944,000 +$674,283 +250% 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $1,090,717 $362,000 +$95,675 +36% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $995,042 $282,000 +$133,166 +89% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $861,876 $177,000 -$23,067 -12% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $884,943 $269,717 +$742 +0.28% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $884,201 $266,325 -$11,896 -4.3% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $896,097 $148,834 -$72,466 -33% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $968,563 $200,067 -$1,206,064 -86% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $2,174,627 $268,975 -$626,246 -70% 01 Oct 2018 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 $2,800,873 $278,221 -$1,142,959 -80% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $3,943,832 $221,300 -$554,085 -71% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $4,497,917 $1,406,131 +$485,332 +53% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $4,012,585 $895,221 -$666,703 -43% 01 Oct 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
Q3 2017 $4,679,288 $1,421,180 -$408,191 -22% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $5,087,479 $775,385 -$526,528 -40% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018 2018 Q2
Q1 2017 $5,614,007 $920,799 -$1,890,309 -67% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $7,504,316 $1,561,924 +$374,743 +32% 01 Oct 2016 31 Dec 2016 10-K 26 Feb 2018 2017 FY
Q3 2016 $7,129,573 $1,829,371 +$905,712 +98% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $6,223,861 $1,301,913 +$178,467 +16% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $6,045,394 $2,811,108 +$2,099,367 +295% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q4 2015 $3,946,027 $1,187,181 +$501,947 +73% 01 Oct 2015 31 Dec 2015 10-K 15 Mar 2017 2016 FY
Q3 2015 $3,444,080 $923,659 +$517,959 +128% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $2,926,121 $1,123,446 +$703,959 +168% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $2,222,162 $711,741 +$151,968 +27% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $2,070,194 $685,234 +$363,763 +113% 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
Q3 2014 $1,706,431 $405,700 -$563,376 -58% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $2,269,807 $419,487 +$72,145 +21% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q1 2014 $2,197,662 $559,773 +$218,298 +64% 01 Jan 2014 31 Mar 2014 10-Q 05 May 2015 2015 Q1
Q4 2013 $1,979,364 $321,471 +$138,339 +76% 01 Oct 2013 31 Dec 2013 10-K 10 Mar 2016 2015 FY
Q3 2013 $1,841,025 $969,076 +$838,717 +643% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $1,002,308 $347,342 +$231,523 +200% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $770,785 $341,475 +$238,645 +232% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q4 2012 $532,140 $183,132 01 Oct 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
Q3 2012 $130,359 +$47,389 +57% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q3
Q2 2012 $115,819 +$55,536 +92% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q2
Q1 2012 $102,830 01 Jan 2012 31 Mar 2012 10-Q 14 May 2013 2013 Q1
Q3 2011 $82,970 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012 2012 Q3
Q2 2011 $60,283 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012 2012 Q2

Cardiff Oncology, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,760,000 +$251,000 +5.6% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $4,509,000 +$253,000 +5.9% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $4,256,000 +$1,022,000 +32% 01 Jan 2022 31 Dec 2022 10-K 29 Feb 2024 2023 FY
2021 $3,234,000 +$1,469,000 +83% 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
2020 $1,765,000 +$880,057 +99% 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2022 2021 FY
2019 $884,943 -$1,289,684 -59% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
2018 $2,174,627 -$1,837,958 -46% 01 Jan 2018 31 Dec 2018 10-K 27 Feb 2020 2019 FY
2017 $4,012,585 -$3,491,731 -47% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
2016 $7,504,316 +$3,558,289 +90% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2018 2017 FY
2015 $3,946,027 +$1,875,833 +91% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2017 2016 FY
2014 $2,070,194 +$90,830 +4.6% 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
2013 $1,979,364 +$1,447,224 +272% 01 Jan 2013 31 Dec 2013 10-K 10 Mar 2016 2015 FY
2012 $532,140 +$281,162 +112% 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
2011 $250,978 01 Jan 2011 31 Dec 2011 10-K 17 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.